81 related articles for article (PubMed ID: 8400777)
1. [Effect of Chinese materia medica on natural killer cell, lymphokine-activated killer cell and activity of interleukin 2].
Huang HY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1993 Apr; 13(4):253-5. PubMed ID: 8400777
[No Abstract] [Full Text] [Related]
2. Bing de ling, a Chinese herbal formula, stimulates multifaceted immunologic responses in mice.
Niu G; Tan J; Turner JG; Brabham JG; Burdelya LG; Crucian BE; Wall-Apelt H; Zhao RJ; Yu H
DNA Cell Biol; 2000 Aug; 19(8):515-20. PubMed ID: 10975469
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine reversibly inhibits natural killer-cell activity.
Citterio F; Cauda R; Tumbarello M; Pozzetto U; Ortona L; Castagneto M
Transplant Proc; 1991 Feb; 23(1 Pt 2):976-7. PubMed ID: 1989350
[No Abstract] [Full Text] [Related]
4. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
5. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma.
Wang Y; Qian XJ; Hadley HR; Lau BH
Mol Biother; 1992 Sep; 4(3):143-6. PubMed ID: 1445669
[TBL] [Abstract][Full Text] [Related]
6. Modulation of perforin, granzyme A, and granzyme B in murine natural killer (NK), IL2 stimulated NK, and lymphokine-activated killer cells by alcohol consumption.
Spitzer JH; Meadows GG
Cell Immunol; 1999 Jun; 194(2):205-12. PubMed ID: 10383823
[TBL] [Abstract][Full Text] [Related]
7. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
Ohnishi H; Lin KM; Chu TM
Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759
[TBL] [Abstract][Full Text] [Related]
8. [On traditional Chinese medicine-mediated biotherapy of leukemia].
Li D
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1996 Jan; 16(1):47-9. PubMed ID: 8732131
[No Abstract] [Full Text] [Related]
9. In vivo activation of LAK cells during systemic IL-2 therapy.
Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
[No Abstract] [Full Text] [Related]
10. Naturin: a potent bio-immunomodifier in experimental studies and clinical trials.
Shen RN; Lu L; Jia XQ; Wong ML; Kaiser HE
In Vivo; 1996; 10(2):201-9. PubMed ID: 8744801
[TBL] [Abstract][Full Text] [Related]
11. Characterization of effector-target conjugates for cloned human natural killer and human lymphokine activated killer cells by flow cytometry.
Callewaert DM; Radcliff G; Waite R; LeFevre J; Poulik MD
Cytometry; 1991; 12(7):666-76. PubMed ID: 1782834
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
Naume B; Gately M; Espevik T
J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
15. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
Carson WE; Fehniger TA; Caligiuri MA
Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
[TBL] [Abstract][Full Text] [Related]
16. [Effects of AT-I on murine cytokins productions and NK cell activity in vivo].
Lei X; Chu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1996 Dec; 27(4):378-82. PubMed ID: 9389007
[TBL] [Abstract][Full Text] [Related]
17. Depressed lymphokine-activated killer activity and analysis of the precursor cells in peripheral blood of patients with hepatocellular carcinoma.
Shirai M; Watanabe S; Nishioka M
Hepatogastroenterology; 1990 Oct; 37(5):465-8. PubMed ID: 2174825
[TBL] [Abstract][Full Text] [Related]
18. Effect of ziram on natural killer, lymphokine-activated killer, and cytotoxic T lymphocyte activity.
Li Q; Kobayashi M; Kawada T
Arch Toxicol; 2012 Mar; 86(3):475-81. PubMed ID: 22038140
[TBL] [Abstract][Full Text] [Related]
19. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
20. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
